Ixekizumab May Improve Early Response After Secukinumab Failure - Summary - MDSpire

Ixekizumab May Improve Early Response After Secukinumab Failure

A real-world cohort found faster early skin responses with ixekizumab than with guselkumab or ustekinumab following secukinumab treatment failure, while all three biologics demonstrated favorable safety.

  • By

  • Andrea Surnit

  • July 22, 2026

  • 4 min

Share

Original Source(s)

Ixekizumab May Improve Early Response After Secukinumab Failure

  • by Andrea Surnit

  • July 22, 2026

Related Content

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness